公开(公告)号：US11844827B2

公开(公告)日：2023-12-19

申请号：US17531897

申请日：2021-11-22

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair Reisner ,  Noga Or-Geva ,  Eran Ophir ,  Yaki Eidelstein ,  Rotem Gidron Budovsky

IPC: A61K39/00 ,  A61K35/17 ,  C12N5/078 ,  C12N5/0783 ,  A61P31/00 ,  A61P35/04 ,  A61K39/395 ,  C07K16/28 ,  A61K35/12

CPC classification number: A61K39/001 ,  A61K35/17 ,  A61K39/39566 ,  A61P31/00 ,  A61P35/04 ,  C07K16/2896 ,  C12N5/0636 ,  C12N5/0637 ,  C12N5/0648 ,  A61K2035/122 ,  A61K2039/5158 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/2321 ,  Y02A50/30

Abstract: An isolated cell having a central memory T-lymphocyte (Tcm) phenotype, the cell being tolerance-inducing cell and capable of homing to the lymph nodes following transplantation, the cell being transduced to express a cell surface receptor comprising a T cell receptor signaling module is disclosed. Methods of generating same and using same are also disclosed.

公开(公告)号：US11179448B2

公开(公告)日：2021-11-23

申请号：US15744905

申请日：2016-07-14

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair Reisner ,  Noga Or-Geva ,  Eran Ophir ,  Yaki Eidelstein ,  Rotem Gidron Budovsky

IPC: A61K39/00 ,  A61K35/17 ,  C12N5/078 ,  C12N5/0783 ,  A61P31/00 ,  A61P35/04 ,  A61K39/395 ,  C07K16/28 ,  A61K35/12

Abstract: An isolated cell having a central memory T-lymphocyte (Tcm) phenotype, the cell being tolerance-inducing cell and capable of homing to the lymph nodes following transplantation, the cell being transduced to express a cell surface receptor comprising a T cell receptor signaling module is disclosed. Methods of generating same and using same are also disclosed.

公开(公告)号：US10434121B2

公开(公告)日：2019-10-08

申请号：US14367923

申请日：2012-12-20

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair Reisner ,  Esther Bachar-Lustig

IPC: A61K35/28 ,  A61K35/17 ,  A61K35/22 ,  A61K35/38 ,  A61K35/39 ,  A61K35/407 ,  A61K35/42 ,  A61K31/675 ,  A61K31/661 ,  A61K35/34 ,  A61K35/36 ,  C12N5/00 ,  A61K31/198 ,  A61K31/255 ,  A61K31/7076 ,  A61K39/395 ,  A61K39/00 ,  A61K35/12

Abstract: A method of treating a subject in need of a non-syngeneic cell or tissue graft is disclosed. The method comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoetic cells, wherein the T cell depleted immature hematopoetic cells comprise less than 5×105 CD3+ T cells per kilogram body weight of the subject, and wherein the dose comprises at least about 5×106 CD34+ cells per kilogram body weight of the subject, and wherein the T cell depleted immature hematopoetic cells are obtained by separating the T cells from the immature hematopoetic cells by magnetic cell sorting, and (b) administering to the subject a therapeutically effective amount of cyclophosphamide, wherein the therapeutically effective amount comprises 25-200 mg per body weight, thereby treating the subject.

公开(公告)号：US10668109B2

公开(公告)日：2020-06-02

申请号：US15737290

申请日：2016-06-16

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair Reisner ,  Chava Rosen ,  Elias Shezen ,  Irit Milman Krentsis

IPC: A61K35/42 ,  A61K45/06 ,  A61K31/015 ,  A61K35/12 ,  A61K35/28 ,  C12N5/071 ,  A61K9/00 ,  A61K31/255 ,  A61K31/675 ,  A61N5/10

Abstract: A method of conditioning a subject in need of transplantation of progenitor cells in suspension of a tissue of interest is disclosed. The method comprising: (a) administering to a subject a therapeutically effective amount of an agent capable of inducing damage to the tissue of interest, wherein the damage results in proliferation of resident stem cells in the tissue; and subsequently (b) subjecting the subject to an agent which ablates the resident stem cells in the tissue. A method of transplanting progenitor cells in suspension of a tissue of interest to a subject in need thereof is also disclosed.

公开(公告)号：US12133866B2

公开(公告)日：2024-11-05

申请号：US17735146

申请日：2022-05-03

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair Reisner ,  Yaki Eidelstein ,  Eran Ophir ,  Assaf Lask ,  Ran Afik ,  Noga Or-Geva ,  Esther Bachar-Lustig

IPC: A61K35/17 ,  A61K35/12 ,  A61K35/22 ,  A61K35/26 ,  A61K35/28 ,  A61K35/34 ,  A61K35/36 ,  A61K35/38 ,  A61K35/39 ,  A61K35/407 ,  A61K35/42 ,  A61K39/00 ,  C12N5/0783

Abstract: A method of generating an isolated population of cells comprising anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance-inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) contacting peripheral blood mononuclear cells (PBMC) with a third party antigen or antigens in the presence of IL-21 so as to allow enrichment of antigen reactive cells; and (b) culturing the cells resulting from step (a) in the presence of IL-21, IL-15 and IL-7 in an antigen free environment so as to allow proliferation of cells comprising the central memory T-lymphocyte (Tcm) phenotype.

公开(公告)号：US11773372B2

公开(公告)日：2023-10-03

申请号：US17211863

申请日：2021-03-25

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair Reisner ,  Noga Or-Geva ,  Rotem Gidron Budovsky ,  Esther Bachar-Lustig ,  Assaf Lask ,  Sivan Kagan

IPC: C12N5/0783 ,  A61K35/17 ,  A61K39/00 ,  C12N5/00 ,  A61K35/12

CPC classification number: C12N5/0637 ,  A61K35/17 ,  A61K39/001 ,  C12N5/0087 ,  A61K2035/122 ,  A61K2039/5158 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/2321 ,  C12N2502/1121

Abstract: A method of generating an isolated population of non graft versus host disease (GvHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) providing a population of at least 70% memory T cells; (b) contacting the population of memory T cells with an antigen or antigens so as to allow enrichment of antigen reactive cells; and (c) culturing the cells resulting from step (b) in the presence of cytokines so as to allow proliferation of cells comprising the Tcm phenotype. Cells generated by the method, pharmaceutical compositions and methods of treatment are also disclosed.

公开(公告)号：US11504399B2

公开(公告)日：2022-11-22

申请号：US16538954

申请日：2019-08-13

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair Reisner ,  Esther Bachar-Lustig

IPC: A61K35/17 ,  A61K35/22 ,  A61K35/28 ,  A61K35/38 ,  A61K35/39 ,  A61K35/407 ,  A61K35/42 ,  A61K31/675 ,  A61K35/34 ,  A61K35/36 ,  C12N5/00 ,  A61K31/198 ,  A61K31/255 ,  A61K31/7076 ,  A61P37/06 ,  A61P37/02 ,  A61K31/661 ,  A61K39/395 ,  A61K39/00 ,  A61K35/12

Abstract: A method of treating a subject in need of a non-syngeneic cell or tissue graft is disclosed. The method comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoietic cells, wherein the T cell depleted immature hematopoietic cells comprise less than 5×105 CD3+ T cells per kilogram body weight of the subject, and wherein the dose comprises at least about 5×CD34+ cells per kilogram body weight of the subject, and wherein the T cell depleted immature hematopoietic cells are obtained by separating the T cells from the immature hematopoietic cells by magnetic cell sorting, and (b) administering to the subject a therapeutically effective amount of cyclophosphamide, wherein the therapeutically effective amount comprises 25-200 mg per body weight, thereby treating the subject.

公开(公告)号：US20140363437A1

公开(公告)日：2014-12-11

申请号：US14367917

申请日：2012-12-20

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair Reisner ,  Esther Bachar-Lustig

IPC: A61K35/28 ,  A61K31/7076 ,  A61K31/661 ,  A61K39/395

CPC classification number: A61K35/28 ,  A61K31/198 ,  A61K31/255 ,  A61K31/661 ,  A61K31/675 ,  A61K31/7076 ,  A61K35/22 ,  A61K35/34 ,  A61K35/36 ,  A61K35/38 ,  A61K35/39 ,  A61K35/407 ,  A61K35/42 ,  A61K39/3955 ,  A61K2035/124 ,  A61K2039/507 ,  A61K2039/515 ,  C12N5/0087 ,  A61K2300/00

Abstract: A method of treating a subject in need of a non-syngeneic cell or tissue graft is disclosed. The method comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoietic cells, wherein the T cell depleted immature hematopoietic cells comprise less than 5×105 CD3+ T cells per kilogram body weight of the subject, and wherein the dose comprises at least about 5×106 CD34+ cells per kilogram body weight of the subject; and subsequently (b) administering to the subject a therapeutically effective amount of cyclophosphamide, wherein the therapeutically effective amount comprises 25-200 mg per kilogram body weight, thereby treating the subject.

Abstract translation: 公开了一种治疗需要非同基因细胞或组织移植物的受试者的方法。 该方法包括：（a）向受试者移植一定剂量的T细胞耗尽的未成熟造血细胞，其中所述T细胞耗尽的未成熟造血细胞每个体重为每公斤体重小于5×10 5个CD3 + T细胞，其中所述剂量 每公斤体重至少约5×106个CD34 +细胞; 并且随后（b）向受试者施用治疗有效量的环磷酰胺，其中治疗有效量包含25-200mg /千克体重，从而治疗受试者。

公开(公告)号：US20140356335A1

公开(公告)日：2014-12-04

申请号：US14363814

申请日：2012-12-06

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair Reisner ,  Elias Shezen ,  Chava Rosen

IPC: A61K35/54

CPC classification number: A61K35/54 ,  A61K35/42 ,  C12N5/0688

Abstract: A pharmaceutical composition comprising as an active ingredient an isolated population of cell suspension from a mammalian fetal pulmonary tissue is disclosed. The fetal pulmonary tissue is at a developmental stage corresponding to that of a human pulmonary organ/tissue at a gestational stage selected from a range of about 20 to about 22 weeks of gestation. Methods of using the pharmaceutical composition are also disclosed.

Abstract translation: 公开了一种药物组合物，其包含来自哺乳动物胎儿肺组织的分离的细胞悬液群作为活性成分。 胎儿肺组织处于与选自妊娠约20至约22周的妊娠阶段的人肺器官/组织相对应的发育阶段。 还公开了使用该药物组合物的方法。

公开(公告)号：US11555178B2

公开(公告)日：2023-01-17

申请号：US16478477

申请日：2018-01-18

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair Reisner ,  Esther Bachar-Lustig ,  Shlomit Reich-Zeliger

IPC: C12N5/0783 ,  A61P35/02 ,  A61P35/04 ,  A61P35/00 ,  A61K35/17 ,  C07K14/725 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  C12N5/00 ,  A61K38/00

Abstract: An isolated cytotoxic T-lymphocyte (CTL), said CTL being a tolerance inducing cell and substantially depleted of alloreactivity, and wherein said CTL does not comprise a central memory T-lymphocyte (Tcm) phenotype, the CTL being transduced to express a cell surface receptor comprising a T cell receptor signaling module, is disclosed. Methods of generating same and using same are also disclosed.